Literature DB >> 35999390

Sarcoidosis: can tofacitinib slay the dragon?

Nadera J Sweiss1, Robert Baughman2.   

Abstract

Entities:  

Year:  2022        PMID： 35999390     DOI： 10.1038/s41584-022-00832-1

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   32.286


× No keyword cloud information.
  3 in total

1.  Tumor necrosis factor inhibition in the treatment of refractory sarcoidosis: slaying the dragon?

Authors:  Nadera J Sweiss; Robert P Baughman
Journal:  J Rheumatol       Date:  2007-11       Impact factor: 4.666

2.  C-reactive protein predicts response to infliximab in patients with chronic sarcoidosis.

Authors:  N J Sweiss; E S Barnathan; K Lo; M A Judson; R Baughman
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2010-07       Impact factor: 0.670

Review 3.  Beneficial Immune Regulation by Biological Response Modifier Glucans in COVID-19 and Their Envisaged Potentials in the Management of Sepsis.

Authors:  Senthilkumar Preethy; Kadalraja Raghavan; Vidyasagar Devaprasad Dedeepiya; Vaddi Surya Prakash; Nobunao Ikewaki; Yasunori Ikeue; Mitsuru Nagataki; Masaru Iwasaki; Rajappa Senthilkumar; Samuel J K Abraham
Journal:  Front Immunol       Date:  2022-06-27       Impact factor: 8.786
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.